<DOC>
	<DOCNO>NCT01496209</DOCNO>
	<brief_summary>A double blinded placebo-controlled , dose escalation , single-center safety preliminary efficacy study cardiospheres deliver via NOGA MYOSTAR injection catheter subject chronic ischemic cardiomyopathy . The objective achieve document myocardial regeneration patient chronic scar .</brief_summary>
	<brief_title>REgenerative CardiOsphere iNjection STRengthen dysfUnCTional Hearts</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Adults ischemic cardiomyopathy ( EF &gt; 10 &lt; 40 % functional imaging [ ECHO , CT , MRI , contrast ventriculography ] ) Symptomatic heart failure NYHA Class 2 3 History prior remote ( &gt; 3 mo ) myocardial infarction and/or document obstructive coronary artery disease correspond dysfunctional segment functional imaging Age &gt; 18 year Ability provide inform consent followup protocol procedure Documented myocardial infarction within 3 month ( 120 day ) Known suspect leave ventricular thrombus Noncardiovascular disease life expectancy &lt; 3 year Absence significant gadoliniumenhanced scar ( &gt; 10 % LV mass ) baseline MRIc Positive panelreactive antibody ( PRA ) Need revascularization clinically indicated time patient assess participation clinical trial . This determined cardiologist investigator clinical trial . No revascularization may indicate artery significant stenosis , location , extent stenosis may suitable angioplasty , distal vessel may suitable placement bypass graft , and/or patient decline angioplasty bypass surgery . NYHA IV heart failure History aortic stenosis/insufficiency Requirement chronic immunosuppressive therapy Participation ongoing protocol study experimental drug device Diagnosis congenital geneticallytransmitted cardiomyopathy Current alcohol drug abuse anticipate difficulty comply protocolrelated procedure Pregnancy childbearing potential without use effective contraception . Men intend `` father '' child also exclude . Human Immunodeficiency virus infection Viral hepatitis Uncontrolled diabetes and/or hemoglobin A1C &gt; 8.5 % Abnormal liver function ( SGPT &gt; 3 time upper reference range ) and/or hematology ( hematocrit &lt; 25 % , WBC &lt; 3000 , Platelets &lt; 100,000 ) study without reversible , identifiable cause Ventricular tachycardia fibrillation associate acute ischemic episode Canadian Cardiovascular Society Angina Class 3 4 History cardiac tumor cardiac tumor demonstrate suspected MRI image modality Previous stem cell therapy/treatment Individuals fluent English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Infarction</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Ventricular Dysfunction , Left</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Chronic Ischemia</keyword>
</DOC>